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Background
The immune correlate analysis of the RV144 trial identi-
fied antibodies (Abs) targeted at the V1-V2 domain as
potentially protective vaccine responses. Reactivity of vac-
cinee serum Abs with a glycosylated gp70-V1-V2 fusion
protein or with certain V2 loop peptides was significantly
associated with a lower risk of viral infection. A V2 loop
segment approximately comprising amino acid residues
165-178 of gp120 was also identified by pilot vaccinee
studies as a key immunogenic region.
Methods
To identify whether the segment identified by pilot studies
coincides with the reagents reactive in the case control
study, I mapped the locations of the reagents associated
with lower risk of viral infection onto the V1-V2 domain
structure. With a single segment identified as associated
both with immunogenicity in the pilot studies and protec-
tion in the case control study, I calculated the Dayhoff
evolutionary sequence distance between the the sequences
of this segment in the immunogens and in a panel of V2
loop based reagents used in the case control study, each
with associated odds ratios (OR) for risk. OR was then
plotted against distance.
Results
The same V2 loop segment from positions 165-178 that
was specifically most immunogenic in the pilot studies
appears to have been associated with protection in the
immune correlate analysis. This segment corresponds to
the “C” strand of the V1-V2 domain beta-sheet fold,
exactly where the broadly neutralizing antibody PG9
binds. Plotting the evolutionary distance between this seg-
ment in the RV144 immunogens and synthetic V2 loop
based antigens used in the case control study shows that
lower risk (lower OR) correlates with greater evolutionary
distance.
Conclusion
A V2 loop segment from positions 165-178 of gp120 was
highly immunogenic in humans. Abs elicited by the
RV144 subtype E immunogen displaying segment may
have been protective only if they cross-reacted distantly
with subtype B.
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